(Total Views: 356)
Posted On: 01/15/2024 6:56:21 PM
Post# of 36541
HER2/neu-based vaccination with li-Key hybrid, GM-CSF immunoadjuvant and trastuzumab as a potent triple-negative breast cancer treatment
Yihan Zhoucorresponding author
Author information Article notes Copyright and License information PMC Disclaimer
Department of Oncology, Medical Sciences Division, University of Oxford
Published online 2023 Jan 24. doi: 10.1007/s00432-023-04574-9
PMCID: PMC10356871PMID: 36692548
//“Trials for E75 and GP2 were limited to eligible populations who are HLA A2 and/or A3 + (Carmichael et al. 2010; Clifton et al. 2017, 2020; Mittendorf et al. 2014, 2016, 2019; Patel et al. 2021a, b), whilst there is no such constrain for AE37 (Holmes et al. 2008; Peace et al. 2017), as HLA A molecules form the major group of MHC class I molecules, which are targeted by E75 and GP2. Therefore, the use of AE37 vaccines to treat breast cancer patients may be less restricted in terms of HLA A subtypes, compared to E75 and GP2“//
—-
I wrote a stupid Seeking alpha blog with the hypothesis a decade ago that hla restrictions of NeuVax (e75) signify that AE37’s market size is 2 or 3 times larger. The tech is still there, not sure about patents, if Youfeng has any common sense or desire to actually advance the science.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356871/
Yihan Zhoucorresponding author
Author information Article notes Copyright and License information PMC Disclaimer
Department of Oncology, Medical Sciences Division, University of Oxford
Published online 2023 Jan 24. doi: 10.1007/s00432-023-04574-9
PMCID: PMC10356871PMID: 36692548
//“Trials for E75 and GP2 were limited to eligible populations who are HLA A2 and/or A3 + (Carmichael et al. 2010; Clifton et al. 2017, 2020; Mittendorf et al. 2014, 2016, 2019; Patel et al. 2021a, b), whilst there is no such constrain for AE37 (Holmes et al. 2008; Peace et al. 2017), as HLA A molecules form the major group of MHC class I molecules, which are targeted by E75 and GP2. Therefore, the use of AE37 vaccines to treat breast cancer patients may be less restricted in terms of HLA A subtypes, compared to E75 and GP2“//
—-
I wrote a stupid Seeking alpha blog with the hypothesis a decade ago that hla restrictions of NeuVax (e75) signify that AE37’s market size is 2 or 3 times larger. The tech is still there, not sure about patents, if Youfeng has any common sense or desire to actually advance the science.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356871/
(1)
(0)Scroll down for more posts ▼
